Clinical trials: Recurrent Epithelial Ovarian Cancer
Fallopian Tube Cancer, Ovarian Cancer
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00091377
- Testing
- cisplatin, paclitaxel, phenoxodiol
- Where
- 2 sites in United States, Australia
- Volunteers
- 65 people
- Sponsor
- MEI Pharma, Inc.
Ovarian Cancer
Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or…
- Trial name
- NCT00002928
- Testing
- paclitaxel
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer
Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
Advanced ovarian cancer is a high medical need indication. Cure is not available to these patients and treatment has palliative intent.
- Trial name
- OVAR (NCT02054351)
- Testing
- IMAB027
- Where
- 9 sites in Belgium, Germany
- Volunteers
- 42 people
- Sponsor
- Ganymed Pharmaceuticals GmbH
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Ovarian Cancer
New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence
In this study, mass spectrometry was used to analyze immune inflammation-related protein complexes, post-translational modified glycopeptide omics and tumor-related metabolomics in serum, respectively, in order to find potential…
- Trial name
- NCT05410028
- Testing
- No intervention in clinical treatment
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Adult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian Cancer
NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.
Ovarian cancer is the seventh most common cancer in women worldwide and is the leading cause of gynecologic cancer deaths in high-income countries.
- Trial name
- NIRAPK (NCT04861181)
- Testing
- Pharmacokinetics, Dosage of Niraparib
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hospices Civils de Lyon
Ovarian Cancer
Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer
The purpose of this study is to determine the maximum tolerated dose of Lapatinib with Carboplatin AUC 6 in patients with platinum sensitive recurrent ovarian or primary peritoneal carcinoma and to determine the nature and degree…
- Trial name
- NCT00317434
- Testing
- lapatinib
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Alabama at Birmingham
Cancer
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
RATIONALE: Methotrexate and glucocorticoid therapy, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant.
- Trial name
- NCT00357084
- Testing
- methotrexate, methylprednisolone, prednisone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Male Breast Cancer, Recurrent Melanoma
Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
This pilot trial studies propranolol hydrochloride in treating patients with locally recurrent or metastatic solid tumors that cannot be removed by surgery.
- Conditions
- Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, Stage IV Melanoma
- Trial name
- NCT02013492
- Testing
- propranolol hydrochloride, Correlative Studies
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- William Carson
Ovarian Cancer, Ovarian Carcinoma
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma
- Trial name
- NCT06964009
- Testing
- DT2216, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Elizabeth Stover, MD, PhD
Ovarian Cancer
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer .
- Trial name
- NCT03940196
- Testing
- NovoTTF-100L(O), Paclitaxel
- Where
- 119 sites in United States, Austria and 11 more
- Volunteers
- 540 people
- Sponsor
- NovoCure Ltd.
Fallopian Tube Cancer, Ovarian Cancer
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing of die. PURPOSE: Randomized phase II trial to compare the effectiveness of two treatment regimens of lurtotecan…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00010179
- Testing
- lurtotecan liposome
- Where
- 14 sites in Canada, United Kingdom
- Volunteers
- 81 people
- Sponsor
- NCIC Clinical Trials Group
Fallopian Tube Cancer, Ovarian Cancer
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00287859
- Testing
- topotecan hydrochloride
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer, Immunotherapy
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
The goal of this clinical trial is to learn if drug regimen weekly paclitaxel/nab-paclitaxel, pembrolizumab, and mirabegron works to treat relapsed ovarian cancer in adults.
- Conditions
- Ovarian Cancer, Immunotherapy, Pembrolizumab
- Trial name
- NCT07261683
- Testing
- Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Obstetrics & Gynecology Hospital of Fudan University
Ovarian Cancer
Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.
Many ovarian cancer patients have been offered different standard cytostatics and gradually develop chemo-resistance. However, a considerable fraction of these patients are still in good general health and have a strong wish for…
- Trial name
- CaTo-ROC (NCT02560337)
- Testing
- Cabazitaxel
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Vejle Hospital
Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
This phase Ib trial studies the side effects and best dose of nivolumab with or without ipilimumab in treating patients with female reproductive cancer that has come back (recurrent) or is high grade and has spread extensively…
- Conditions
- Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma
- Trial name
- NCT03508570
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: A walking program may improve the ability to carry out daily activities after donor bone marrow transplant. PURPOSE: This randomized clinical trial is studying a structured walking program to see how well it works…
- Trial name
- NCT00445731
- Testing
- exercise intervention, management of therapy complications, observation
- Volunteers
- 115 people
- Sponsor
- University of Minnesota
Ovarian Cancer, Primary Peritoneal Carcinoma
Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients
This is a single arm phase II, multicenter study evaluating Pembrolizumab in recurrent platinum resistant CPS score >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients.
- Conditions
- Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- MITO 27 (NCT04375956)
- Testing
- Pembrolizumab
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent).
- Conditions
- Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT05231122
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Roswell Park Cancer Institute
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
- Trial name
- DUAL-OV-CAR-NK (NCT07480954)
- Testing
- Dual-target CAR-NK cell product, Lymphodepleting chemotherapy, Standard supportive care
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.